On October 10, 2025, H.B. Fuller Company announced that Celine Martin will join its Board of Directors, with her appointment becoming effective on December 1, 2025. The announcement was made via a BusinessWire release and confirms the addition of a senior MedTech executive to the company’s governance structure.
Celine Martin brings more than three decades of experience in the global medical device industry. She most recently served as Company Group Chairman of Johnson & Johnson’s Cardiovascular & Specialty Solutions Group, overseeing portfolios that include electrophysiology, neurovascular intervention, and breast aesthetics. Prior to that, she led the surgical instrument portfolio at Ethicon, the maker of Dermabond topical adhesives, from 2018 to 2021.
Her expertise aligns closely with H.B. Fuller’s strategic emphasis on expanding its medical adhesive technologies segment. The company has identified medical adhesives as a high‑growth, high‑margin area and has already acquired several medical‑focused businesses. Adding Martin to the board reinforces the company’s commitment to accelerating innovation and market penetration in this segment as part of its broader transformation toward a >20% adjusted EBITDA margin.
For investors, the appointment signals a strengthening of the board’s industry knowledge in a key growth area. Martin’s background in product development, commercialization, and regulatory strategy is expected to accelerate the company’s pipeline of medical adhesive solutions, potentially driving future revenue and margin expansion in a market that has already shown significant upside for H.B. Fuller.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.